P364 NON-ANIMALSTABILIZED HYALURONIC ACID FOR KNEE OSTEOARTHRITIS: COMBINED ANALYSIS OF TWO PLACEBO-CONTROLLEDTRIALS  by Altman, R. et al.
S194 Poster Presentations
COX-2 inhibitor lumiracoxib (400 mg once daily [od]) has com-
parable efficacy to indomethacin (50 mg three times daily [tid])
for the treatment of acute flares of gout. Secondary analysis of
safety and tolerability included a specific, pre-defined comparison
of differences in blood pressure.
Methods: This was a 1-week, multicentre, randomized, double-
blind, double-dummy, active-controlled, parallel-group study of
lumiracoxib 400 mg od (n=118) vs indomethacin 50 mg tid
(n=117) (safety population) in patients with acute flares of gout.
The primary analysis was a test of non-inferiority in the per
protocol population of the mean change from baseline in pain
intensity in the study joint over Days 2-5.
The blood pressure profile was assessed by a pre-defined anal-
ysis of the mean change from baseline for systolic and diastolic
blood pressure.
Results: In the per protocol population, lumiracoxib 400 mg od
(n=112) was non-inferior to indomethacin 50 mg tid (n=110).
Least square mean (LSM) change from baseline in pain intensity
for lumiracoxib was 1.29 (1.47) vs 1.29 (1.50) over Days 2-5
(Days 2-7) treatment period for lumiracoxib and indomethacin,
respectively. Both drugs were also comparable in all secondary
efficacy assessments.
50% of the patients had a medical history of hypertension.
The table below shows the mean change from baseline in BP
for lumiracoxib vs indomethacin at study end, after 7 days of
treatment (safety population*).
Mean change/(SD) Lumiracoxib Indomethacin Two sided T-test
400 mg od n=114 50 mg tid n=116 p-value
Systolic blood
pressure (mmHg) -1.0 (9.74) 2.5 (10.68) 0.009
Diastolic blood
pressure (mmHg) -1.3 (6.06) 0.5 (6.57) 0.028
*Only patients with BP measurement at both baseline and study end were in-
cluded.
None of the patients in the lumiracoxib group showed a clinically
relevant increase in blood pressure (defined as change from
baseline of at least 25%), as compared to 1.7% of patients in the
indomethacin group.
Only 1.7% of the patients on lumiracoxib 400 mg od discontinued
study drug compared with 8.5% on indomethacin 50 mg tid. AEs
were reported in 10.2% of patients in the lumiracoxib group
compared with 22.2% of patients in the indomethacin group. Due
to suspected Good Clinical Practice non-compliance, a post-
hoc sensitivity analysis was performed after database closure
excluding a center containing 8 patients. The sensitivity analysis
revealed no substantial change of the study results, the only
exception was diastolic blood pressure (p=0.057).
Conclusions: Lumiracoxib 400 mg od is effective in the treat-
ment of acute gout with efficacy comparable to indomethacin
50 mg tid. In addition, even after short-term treatment, lumira-
coxib shows a favourable blood pressure profile as compared to
indomethacin, and with fewer AEs and discontinuations. Lumira-
coxib may thus provide an alternative effective treatment option
for acute gout.
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THE ASSOCIATION BETWEEN ECTOPIC BONE
FORMATION AFTER HIP REPLACEMENT SURGERY AND
CLINICAL OUTCOMES. RESULTS FROM THE HIPAID
CLINICAL TRIAL
M. Fransen
The HIPAID Collaborative Group; The George Institute,
Camperdown Sydney, Australia
Purpose: To determine if there is an association between the
severity of ectopic bone formation after hip replacement surgery,
chronic hip pain and physical disability.
Methods: HIPAID was a double-blind randomised placebo-
controlled clinical trial conducted in 20 orthopaedic surgery cen-
tres in Australia and New Zealand.
902 patients undergoing elective primary or revision total hip re-
placement surgery were randomly allocated to 14 days treatment
with ibuprofen (1200mg daily) or matching placebo commenced
within 24 hours of surgery. Participants were required to have hip
radiographs, complete self-reported questionnaires measuring of
pain and physical function (WOMAC), report analgesia use and
undergo several physical performance measures (hip flexion, up
and go, 50ft walk time) six to twelve months after surgery.
Results: Hip radiographs were obtained from 798 (88%) par-
ticipants and scored for ectopic bone formation severity using
the Brooker grading (0-4). Among the 294 (37%) of HIPAID par-
ticipants with radiographic evidence of ectopic bone formation,
108 (37%) had at least moderate severity (Brooker grade 2, 3
or 4). Brooker grade 3 and 4 demonstrated increased pain and
function scores, compared with less severe grades of ectopic
bone formation; however this trend was not significant. There
were was also a trend in the physical performance measures,
but again this trend was not significant.
Ectopic bone formation and clinical outcomes
Brooker Grade Pain (0-10) Function (0-10)
mean (sd) mean (sd)
0 0.97 (1.47) 1.56 (1.57)
1 0.99 (1.49) 1.43 (1.57)
2 0.97 (1.57) 1.87 (1.79)
3 and 4 1.25 (1.85) 2.23 (1.95)
Conclusions: These data, from the largest-ever trial of pro-
phylaxis against ectopic bone formation, suggest that only a
small proportion of patients undergoing elective hip replacement
surgery will develop clinically relevant ectopic bone around the
new hip implant.
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NON-ANIMAL STABILIZED HYALURONIC ACID FOR
KNEE OSTEOARTHRITIS: COMBINED ANALYSIS OF
TWO PLACEBO-CONTROLLED TRIALS
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Purpose: With the increased controversy associated with long-
term use of NSAIDs and COX-2 inhibitors, there is renewed
interest in the use of intraarticular (IA) injections, including
hyaluronans (HA), for the management of patients with knee os-
teoarthritis (OA). Non-animal stabilized hyaluronic acid (NASHA;
Durolane®) is administered as a single IA injection for OA of
the knee, and has an extended IA residence time (half-life: 4
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weeks). In uncontrolled studies, single-injection NASHA was well
tolerated and provided significant pain relief for ≥6 months. The
results of two randomized, placebo-controlled trials were com-
bined to examine NASHA versus placebo in a pre-defined effec-
tiveness population (EP), which included all randomized, treated
patients with OA confined to the knee and without effusion.
Methods: We combined data from two double-blind, randomized
trials comparing a single IA injection of NASHA (3 ml, 60 mg) with
3 ml of IA saline. All patients had knee OA by ACR classification
criteria. Study 1 lasted for 6 months and study 2 for 6 weeks.
Study 2 included only patients with unilateral knee OA. Patients
with joint effusion at the time of treatment were excluded from
the combined analysis, as effusion may attenuate the benefit of
HA through a combination of dilution and increased degradation.
The primary efficacy endpoint for the combined analysis was the
responder rate at 6 weeks, defined as the percentage of patients
with ≥40% reduction in pain and an absolute reduction of ≥5 in
WOMAC (Likert) pain score. Responder rates for WOMAC phys-
ical function score were calculated (improvements of 20%, 30%
and 40% at week 6 vs baseline). The analysis was performed
using the intention-to-treat population.
Results: The EP comprised a total of 284 patients (NASHA,
n=151; placebo, n=133). At 6 weeks, the responder rate was
significantly greater with NASHA than placebo group (last obser-
vation carried forward: 43.0% vs 24.8%, p=0.0013). In study 1,
reduction in pain (p<0.0001 vs baseline) persisted throughout
the 6-month follow-up period. The percentage of patients in the
EP showing an improvement of ≥1 in global status at 6 weeks
was 37.7% in the NASHA group, versus 27.1% for placebo
(p=0.0556). For WOMAC physical function, the 20% respon-
der rate was significantly higher with NASHA versus placebo
(62.3% vs 50.4%, p=0.0439), with a trend in favour of NASHA
for the other two criteria. The percentage of patients reporting
≥1 adverse event (AE) was 45.2% with NASHA and 43.3%
with placebo. There were no inflammatory reactions and no
treatment-related serious AEs.
Conclusions: In an analysis of two placebo-controlled trials,
NASHA provided significant reduction in pain versus placebo
at 6 weeks post-injection, with persistent pain relief in patients
followed for 6 months. These outcomes are similar to those
reported for other IA HA preparations, but NASHA has the added
benefits of no animal peptide contaminants and a single-injection
regimen. NASHA was well tolerated, with no treatment-related
serious AEs.
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REGENERATION OF ARTICULAR CARTILAGE AFTER
PELVIC OSTEOTOMY IN OSTEOARTHRITIS HIPS DUE TO
ACETABULAR DYSPLASIA
S. Jingushi, Y. Noguchi, E. Suenaga, Y. Iwamoto
Kyushu University, Fukuoka, Japan
Purpose: Biomechanical abnormality in the joint is one of the
major causes for osteoarthritis. Abnormally large pressure on
joints and joint instability will result in degeneration of the articular
cartilage followed by joint destruction and deformity. Osteotomy
has been carried out to restore such biomechanical abnormality.
P365 – Table 1. Regeneration score at the site where subchondral bone was exposed before osteotomy
Regeneration score Acetabular cartilage (% in parenthesis) Femoral head cartilage (% in parenthesis)
AS SU PS AS SU PS
Total number 21 19 9 13 9 2
2 0 (0) 0 (0) 0 (0) 2 (15) 1 (11) 0 (0)
1 11 (52) 9 (49) 4 (44) 4 (31) 4 (44) 1 (50)
0.5 6 (29) 5 (26) 4 (44) 4 (31) 3 (33) 1 (50)
0 4 (19) 5 (26) 1 (11) 3 (23) 1 (11) 0 (0)
The main purpose is to prevent osteoarthritis deterioration. In hip
joints, osteoarthritis often occurs due to acetabular dysplasia.
In order to restore the acetabular dysplasia, periacetabular os-
teotomy is carried out. The clinical outcomes are reported to be
optimal. Additionally, a few case reports showed that osteotomy
could result in not only prevention of osteoarthritis deterioration
but also regeneration of the injured articular cartilage. In this
study, regeneration of articular cartilage was investigated in the
osteoarthritis hips due to acetabular dysplasia using arthroscopy
before and after osteotomy.
Methods: All the twenty seven hips, that had an operation to
remove the metal ware after pelvic osteotomy since January in
1999 till May in 2000, were investigated. Two, twenty, and five
hips were at pre-osteoarthritis stage, at early stage and at ad-
vanced stage, respectively, when the hips had pelvic osteotomy.
The mean age at the operation for metal ware removal was
44 (20-55) years. The mean period since the pelvic osteotomy
till the operation for the metal ware removal was 18 (11-60)
months. Degeneration of the articular cartilage was evaluated
using arthroscopy during the operation for metal ware removal,
and the arthroscopic observation was compared with that just
before the pelvic osteotomy. Degeneration of acetabular and
femoral head cartilage was classified into four grades by allot-
ting a respective 0 to 3 points (degenerative score): grade 0,
no degeneration; grade 1, color change, softening, fine irreg-
ularity; grade 2, fibrillation, erosion, and grade 3, subchondral
bone exposure. The articular cartilage in the weight-bearing area
was divided into three 45 degrees ranges; antero-superior (AS),
superior (SU), and postero-superior (PS). Additionally for arthro-
scopic observation at the operation for metal ware removal, it was
assessed as grade 2.5 when regeneration articular cartilage was
observed, but subchondral bone exposure was remained. Re-
generation score was calculated as follows; (degradation score
at the operation for metal ware removal) - (degradation score
before the pelvic osteotomy).
Results: The mean total degeneration score in all the six lesions
of acetabular and femoral head cartilage before pelvic osteotomy
and at the operation for metal ware removal was 11.7 (0-18) and
9.6 (0-17), respectively. The mean total regeneration score was
2.1 (-2 -6). Subchondral bone exposure was observed before the
pelvic osteotomy in 78%, 70%, and 33% in the AS, SU and PS
lesion of the acetabulum cartilage, and in 48%, 33%, and 7% of
the femoral head cartilage. In such lesions where subchondral
bone exposure was observed before the pelvic osteotomy, the
mean ratio of the lesions, where regeneration of the articular
cartilage was observed, was 85 (74-100) % (Table 1).
Conclusions: The degeneration scores decreased significantly
a few years after pelvic osteotomy indicating that the osteotomy
caused regeneration of articular cartilage. In the most lesions
where the subchondral bone was exposed, cartilage regener-
ation was observed. Pelvic osteotomy may switch the articular
cartilage metabolism to be from osteoarthritis deterioration mode
to regeneration mode. Pelvic osteotomy resulted in not only os-
teoarthritis deterioration but also regeneration of the articular
cartilage.
